We use cookies for a better user experience. Read our Privacy Policy

I Agree

Neurological Disorder Drugs Market

Neurological Disorder Drugs Market (Disorder: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, and Others; Drug Class: Anticholinergic, Antiepileptic, Antipsychotic, Hypnotic & Sedatives, Analgesics, Antihypertensive, Anticoagulants, and Others; and Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 -2027

Glucose Metabolism Modification in Stressed Neurons Caters to Development of New Drugs

Brain injuries of various types and neurological diseases are one of the main causes of deaths worldwide. Hence, researchers are tapping into opportunities through glucose metabolism modification for the development of new drugs that could revolutionize the treatment of neurological disorders. For instance, Gero Discovery - a supplier of novel therapeutic options for neurodegenerative diseases, announced that they have found a potential drug that can help prevent neuronal deaths with the technique of glucose metabolism modification in stressed neurons. Thus, companies in the neurological disorder drugs market should collaborate with talented researchers to develop new drugs.

Companies in the neurological disorder drugs market are increasing animal testing and obtaining promising results for future use of drugs made with glucose metabolism modification in humans. This new technique has the potential to treat Amyotrophic lateral sclerosis, Alzheimer’s, and traumatic brain injuries, among others, in the market for neurological disorder drugs. As such, companies in the market for neurological disorder drugs are capitalizing on the demand for drugs used in the treatment of Alzheimer’s, since the disorder is estimated to account for the second-highest revenue in the market by 2027.

neurological disorder drugs market infographic

To know the scope of our report Get a Sample on Neurological Disorder Drugs Market 

Innovations in 3D CNS Organoids Revolutionize Neurological Disorder Drugs Market

The Central Nervous System (CNS) drug discovery is largely dependent on traditional approaches related to rodent models or cell-based in vitro models. This practice creates a challenge for drug manufacturers, since species differences between humans and rodents are difficult for the correlation of robust data in neurodevelopmental studies. This explains a modest ~5% CAGR of the neurological disorder drugs market. Hence, companies are advancing in the field of stem cells and 3D CNS organoids, since novel tools have close resemblance to the human brain architecture and functions.

CNS organoids provide innovative opportunities to mimic the human brain physiology and acts as a unique modeling tool for the assessment of normal versus pathological brain. CNS organoids are being highly publicized in the market for neurological disorder drugs for elucidation of mechanisms of neurological disorders. This is evident since the revenue of cerebrovascular disorders is projected to aggressively grow in the market for neurological disorder drugs.

Investors Address Need for Effective CNS Drugs as Companies Research Neuroscience

Several large-cap pharmaceutical companies are partnering with small biotech companies and academic institutes to innovate in CNS drugs, while regulatory bodies are searching for ways to address the void in effective drug development. Companies in the neurological disorder drugs market are increasing R&D in neuroscience, since the U.S. FDA approved Sage Therapeutics Inc.'s first-of-its-kind postpartum depression therapy Zulresso. With the U.S. being one of the leading countries in North America, the neurological disorder drugs market in the region is anticipated for exponential growth. Moreover, further innovations in CNS drugs, the neurological disorder drugs market is estimated to reach a value of ~US$ 112 Bn by the end of 2027.

Get a glimpse of the in-depth analysis through our Report Brochure

The field of neuroscience is undergoing a phase of renaissance. This is evident since the FDA stated that organization is witnessing an explosion of new scientific knowledge addressing difficult-to-treat CNS disorders. Investors in the market for neurological disorder drugs are taking note of the FDA’s shifting attitude toward tough-to-treat CNS disorders.

Activating Wild Type GCase Holds Promising Potential for Treatment of Parkinson’s Disease

Companies in the neurological disorder drugs market are adopting new therapeutic approaches for the treatment of the Parkinson’s disease. They are increasing research to understand genetic risk factors associated with the disease for improved drug development. Hence, alterations in the GBA1 gene is emerging as a promising approach for drug development. However, mutations in the gene may result in defects of GCase (glucocerebrosidase) enzymes. Hence, companies in the neurological disorder drugs market are focusing on activating wild type GCase for the development of new drug compounds that can be used in the treatment of Parkinson’s.

The market for neurological disorder drugs is undergoing a change with increased experiments associated with the activation of wild type GCase, resulting in therapeutic benefits among patients.

neurological disorder drugs market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

Antiepileptic and anticholinergic drugs are projected to witness exponential growth in demand in the neurological disorder drugs market. Since big pharmaceutical companies are exiting the neurology space, small biotech companies are stepping up to introduce new neurology drugs. However, clinical trials in neuroscience are expensive to run and the success rate is much lower than that of other disease indications. Hence, companies should identify new genes that lead to new pathways in drug delivery for Alzheimer’s and Parkinson’s. Apart from North America, companies should invest in Asia Pacific since the region is projected for exponential growth during the forecast period. Influx of money flow in the field of CNS is one of the key drivers contributing to market growth.

Neurological Disorder Drugs Market: Overview

  • Neurological disorder drugs can be used for various diseases such as epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, cerebrovascular diseases, and others
  • Around 450 different medications are available for the treatment of neurologic disorders. The epilepsy segment dominated the global neurological disorder drugs market in 2018. Growth of the segment can be attributed to increase in demand for the treatment of cerebrovascular diseases such as stroke.

Neurological Disorder Drugs Market Drivers

  • Increase in the geriatric population leads to manifestation of various neurology disorders, which, in turn, fuels the global market. Cerebrovascular diseases such as stroke and migraine are high in countries such as Germany, the U.K., and Italy in all age groups. France, Sweden, Greece, Denmark, and Russia have high incidence rate of cerebrovascular diseases in people aged between 45 and 84. A study published in NCBI in 2018 indicated that prevalence of stroke was 7.67% among adults aged 65 years and above in Singapore.

Rise in Research & Development Programs

  • Demand for neurological disorder drugs and competition between key players is increasing. Market players focus on molecule growth, with key technological improvements in drugs in order to fulfil customer demand.
  • In March 2019, the U.S. FDA approved Novartis AG’s Mayzent for the treatment of adults with relapsing forms of multiple sclerosis, including SPMS with active disease, relapsing remitting multiple sclerosis (RRMS), and clinically isolated syndrome (CIS)

Market Segmentation: Neurological Disorder Drugs Market

  • Based on disorder, the global neurological disorder drugs market has been divided into epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, cerebrovascular diseases, and others
  • In terms of drug class, the global neurological disorder drugs market has been classified into anticholinergic, antiepileptic, antipsychotic, hypnotic & sedative, analgesics, antihypertensive, anticoagulants, and others
  • Based on distribution channel, the global neurological disorder drugs market has been categorized into retail pharmacies, hospital pharmacies, and online pharmacies
  • Each of the segments has been analyzed in detail for market trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2019 to 2027, along with market size estimations.

Regional Overview: Neurological Disorder Drugs Market

  • In terms of region, the global neurological disorder drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • The current and future market sizes in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report for the period from 2017 to 2027, along with their CAGRs for the period from 2019 to 2027
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which will help new companies willing to enter the market and existing companies to increase market shares, and help in the decision-making process 

Major Players in Neurological Disorder Drugs Market

  • The report concludes with the company profiles section that includes key information about the major players in the market
  • Leading players analyzed in the report are
    • Novartis AG
    • GlaxoSmithKline plc
    • F. Hoffmann-La Roche Ltd.
    • Pfizer
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • AstraZeneca
    • Teva Pharmaceutical Industries
    • Merck & Co., Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • Amgen, Inc.
    • UCB S.A.
    • Eli Lilly and Company
    • Biogen
  • Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Neurological Disorder Drugs Market - Segmentation

TMR’s study on the global neurological disorder drugs market includes information divided into five segments: disorder, drug class, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global neurological disorder drugs market have been discussed in detail.

Disorder

Epilepsy

Alzheimer’s Disease

Parkinson’s Disease

Multiple Sclerosis

Cerebrovascular Diseases

Others

Drug Class

Anticholinergic

Antiepileptic

Antipsychotic

Hypnotic & Sedatives

Analgesics

Antihypertensive

Anticoagulants

Others

Distribution Channel

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Neurological Disorder Drugs Market 

4. Market Overview

    4.1.  Introduction & Overview

    4.2. Product Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities 

    4.4. Global Neurological Disorder Drugs Market Analysis and Forecast, 2017–2027

5. Market Outlook 

    5.1. Pipeline Analysis 

    5.2. Disease Prevalence & Incidence Rate globally with key countries

    5.3. Regulatory Scenario 

6. Global Neurological Disorder Drugs Market Analysis and Forecast, by Disorder

    6.1. Introduction & Definition

    6.2. Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

        6.2.1. Epilepsy 

        6.2.2. Alzheimer Disease 

        6.2.3. Multiple Sclerosis

        6.2.4. Parkinson Disease

        6.2.5.  Cerebrovascular Diseases

        6.2.6. Others

    6.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder

7. Global Neurological Disorder Drugs Market Analysis and Forecast, by Drug Class

    7.1. Introduction & Definition

    7.2. Global Neurological Disorder Drugs Market Value (US$) Forecast, by Drug Class, 2017–2027

        7.2.1. Anticholinergic 

        7.2.2. Antiepileptic 

        7.2.3. Antipsychotic

        7.2.4. Analgesic

        7.2.5. Hypnotic & Sedative

        7.2.6. Antihypertensive

        7.2.7. Anticoagulants

        7.2.8. Others

    7.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class

8. Global Neurological Disorder Drugs Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        8.2.1. Hospital Pharmacies

        8.2.2. Retail Pharmacies

        8.2.3. Online Pharmacies

    8.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel

9. Global Neurological Disorder Drugs Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Region

10. North America Neurological Disorder Drugs Market Analysis and Forecast

    10.1. Introduction

    10.2. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

        10.2.1. Epilepsy 

        10.2.2. Alzheimer Disease 

        10.2.3. Multiple Sclerosis

        10.2.4. Parkinson Disease

        10.2.5.  Cerebrovascular Diseases

        10.2.6. Others 

    10.3. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

        10.3.1. Anticholinergic 

        10.3.2. Antiepileptic 

        10.3.3. Antipsychotic

        10.3.4. Analgesic

        10.3.5. Hypnotic & Sedative

        10.3.6. Antihypertensive

        10.3.7. Anticoagulants

        10.3.8. Others

    10.4. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Neurological Disorder Drugs Market Attractiveness Analysis

        10.6.1. By Disorder

        10.6.2. By Drug Class

        10.6.3. By Distribution Channel

        10.6.4. By Country 

11. Europe Neurological Disorder Drugs Market Analysis and Forecast

    11.1. Introduction

    11.2. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

        11.2.1. Epilepsy 

        11.2.2. Alzheimer Disease 

        11.2.3. Multiple Sclerosis

        11.2.4. Parkinson Disease

        11.2.5.  Cerebrovascular Diseases

        11.2.6. Others 

    11.3. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

        11.3.1. Anticholinergic 

        11.3.2. Antiepileptic 

        11.3.3. Antipsychotic

        11.3.4. Analgesic

        11.3.5. Hypnotic & Sedative

        11.3.6. Antihypertensive

        11.3.7. Anticoagulants

        11.3.8. Others

    11.4. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Europe Neurological Disorder Drugs Market Attractiveness Analysis

        11.6.1. By Disorder

        11.6.2. By Drug Class

        11.6.3. By Distribution Channel 

        11.6.4. By Country/Sub-region

12. Asia Pacific Neurological Disorder Drugs Market Analysis and Forecast

    12.1. Introduction

    12.2. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

        12.2.1. Epilepsy 

        12.2.2. Alzheimer Disease 

        12.2.3. Multiple Sclerosis

        12.2.4. Parkinson Disease

        12.2.5.  Cerebrovascular Diseases

        12.2.6. Others 

    12.3. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

        12.3.1. Anticholinergic 

        12.3.2. Antiepileptic 

        12.3.3. Antipsychotic

        12.3.4. Analgesic

        12.3.5. Hypnotic & Sedative

        12.3.6. Antihypertensive

        12.3.7. Anticoagulants

        12.3.8. Others

    12.4. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific Neurological Disorder Drugs Market Attractiveness Analysis

        12.6.1. By Disorder

        12.6.2. By Drug Class

        12.6.3. By Distribution Channel 

        12.6.4. By Country/Sub-region

13. Latin America Neurological Disorder Drugs Market Analysis and Forecast

    13.1. Introduction

    13.2. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

        13.2.1. Epilepsy 

        13.2.2. Alzheimer Disease 

        13.2.3. Multiple Sclerosis

        13.2.4. Parkinson Disease

        13.2.5.  Cerebrovascular Diseases

        13.2.6. Others 

    13.3. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

        13.3.1. Anticholinergic 

        13.3.2. Antiepileptic 

        13.3.3. Antipsychotic

        13.3.4. Analgesic

        13.3.5. Hypnotic & Sedative

        13.3.6. Antihypertensive

        13.3.7. Anticoagulants

        13.3.8. Others

    13.4. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Latin America Neurological Disorder Drugs Market Attractiveness Analysis

        13.6.1. By Disorder

        13.6.2. By Drug Class

        13.6.3. By Distribution Channel 

        13.6.4. By Country/Sub-region

14. Middle East & Africa Neurological Disorder Drugs Market Analysis and Forecast

    14.1. Introduction

    14.2. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

        14.2.1. Epilepsy 

        14.2.2. Alzheimer Disease 

        14.2.3. Multiple Sclerosis

        14.2.4. Parkinson Disease

        14.2.5.  Cerebrovascular Diseases

        14.2.6. Others

    14.3. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

        14.3.1. Anticholinergic 

        14.3.2. Antiepileptic 

        14.3.3. Antipsychotic

        14.3.4. Analgesic

        14.3.5. Hypnotic & Sedative

        14.3.6. Antihypertensive

        14.3.7. Anticoagulants

        14.3.8. Others

    14.4. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Middle East & Africa Neurological Disorder Drugs Market Attractiveness Analysis

        14.6.1. By Disorder

        14.6.2. By Drug Class

        14.6.3. By Distribution Channel 

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Competition Matrix

    15.2. Market Share Analysis, by Company, 2018

    15.3. Company Profiles

        15.3.1. Novartis AG 

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Company Financials

            15.3.1.3. Growth Strategies

            15.3.1.4. SWOT Analysis

        15.3.2. GlaxoSmithKline plc 

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Company Financials

            15.3.2.3. Growth Strategies

            15.3.2.4. SWOT Analysis

        15.3.3. F. Hoffmann-La Roche Ltd. 

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Company Financials

            15.3.3.3. Growth Strategies

            15.3.3.4. SWOT Analysis

        15.3.4. Pfizer, Inc. 

            15.3.4.1. Company Overview (HQ, Business Segments)

            15.3.4.2. Company Financials

            15.3.4.3. Growth Strategies

            15.3.4.4. SWOT Analysis

        15.3.5. Bayer AG

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Company Financials

            15.3.5.3. Growth Strategies

            15.3.5.4. SWOT Analysis

        15.3.6. Boehringer Ingelheim International GmbH

            15.3.6.1. Company Overview (HQ, Business Segments)

            15.3.6.2. Company Financials

            15.3.6.3. Growth Strategies

            15.3.6.4. SWOT Analysis

        15.3.7. AstraZeneca plc 

            15.3.7.1. Company Overview (HQ, Business Segments)

            15.3.7.2. Company Financials

            15.3.7.3. Growth Strategies

            15.3.7.4. SWOT Analysis

        15.3.8. Teva Pharmaceutical Industries Ltd. 

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Company Financials

            15.3.8.3. Growth Strategies

            15.3.8.4. SWOT Analysis

        15.3.9. Merck & Co., Inc. 

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Company Financials

            15.3.9.3. Growth Strategies

            15.3.9.4. SWOT Analysis

        15.3.10. Otsuka Pharmaceutical Co., Ltd. 

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Company Financials

            15.3.10.3. Growth Strategies

            15.3.10.4. SWOT Analysis

        15.3.11. Amgen, Inc.

            15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.11.2. Company Financials

            15.3.11.3. Growth Strategies

            15.3.11.4. SWOT Analysis

        15.3.12. UCB S.A. 

            15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.12.2. Company Financials

            15.3.12.3. Growth Strategies

            15.3.12.4. SWOT Analysis

        15.3.13. Eli Lilly and Company 

            15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.13.2. Company Financials

            15.3.13.3. Growth Strategies

            15.3.13.4. SWOT Analysis

        15.3.14. Biogen 

            15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.14.2. Company Financials

            15.3.14.3. Growth Strategies

            15.3.14.4. SWOT Analysis

List of Tables

Table 01: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 02: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 03: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 04: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 05: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 06: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 07: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 08: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 09: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 10: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 11: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 12: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 13: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 14: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 15: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 16: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 17: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 18: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 19: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 20: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 21: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 22: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 23: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 24: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

List of Figures

Figure 01: Global Neurological Disorder Drugs Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027

Figure 02: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, 2017–2027

Figure 03: Global Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027

Figure 04: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Epilepsy, 2017–2027

Figure 05: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Alzheimer’s Disease, 2017–2027

Figure 06: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Parkinson’s Disease, 2017–2027

Figure 07: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Multiple Sclerosis, 2017–2027

Figure 08: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cerebrovascular Diseases, 2017–2027 

Figure 09: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027 

Figure 10: Global Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019–2027

Figure 11: Global Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 12: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anticholinergic, 2017–2027 

Figure 13: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antiepileptic, 2017–2027 

Figure 14: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antipsychotic, 2017–2027 

Figure 15: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Analgesic, 2017–2027 

Figure 16: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hypnotic & Sedative, 2017–2027 

Figure 17: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antihypertensive, 2017–2027 

Figure 18: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anticoagulant, 2017–2027 

Figure 19: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027 

Figure 20: Global Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 21: Global Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 22: Global Neurological Disorder Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Retail Pharmacies, 2017–2027

Figure 23: Global Neurological Disorder Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacies, 2017–2027

Figure 24: Global Neurological Disorder Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacies, 2017–2027

Figure 25: Global Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 26: Global Neurological Disorder Drugs Market, by Region, 2018 and 2027

Figure 27: Global Neurological Disorder Drugs Market Attractiveness Analysis, by Region, 2019–2027

Figure 28: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 29: North America Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027

Figure 30: North America Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019–2027

Figure 31: North America Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 32: North America Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 33: North America Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 34: North America Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 35: North America Neurological Disorder Drugs Market Value Share Analysis, by Country, 2018 and 2027

Figure 36: North America Neurological Disorder Drugs Market Attractiveness Analysis, by Country, 2019–2027

Figure 37: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 38: Europe Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027

Figure 39: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019–2027

Figure 40: Europe Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 41: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 42: Europe Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 43: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 44: Europe Neurological Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 45: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 46: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 47: Asia Pacific Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027

Figure 48: Asia Pacific Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019–2027

Figure 49: Asia Pacific Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 50: Asia Pacific Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 51: Asia Pacific Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 52: Asia Pacific Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 53: Asia Pacific Neurological Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 54: Asia Pacific Neurological Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 55: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 56: Latin America Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027

Figure 57: Latin America Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019–2027

Figure 58: Latin America Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 59: Latin America Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 60: Latin America Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 61: Latin America Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 62: Latin America Neurological Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 63: Latin America Neurological Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 64: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 65: Middle East & Africa Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027

Figure 66: Middle East & Africa Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019–2027

Figure 67: Middle East & Africa Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 68: Middle East & Africa Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 69: Middle East & Africa Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 70: Middle East & Africa Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 71: Middle East & Africa Neurological Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 72: Middle East & Africa Neurological Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved